Business Wire

GNT Pharma's Ropesalazine Effective in Treating Dog Dementia

Del

GNT Pharma said Ropesalazine, a drug candidate for Alzheimer’s disease (AD), has shown an outstanding beneficial efficacy in a pilot clinical trial conducted for dogs with cognitive dysfunction syndrome (CDS) or dementia.

CDS is a progressive neurodegenerative disorder of senior dogs and characterized by altered interaction with family, disorientation, sleep/wake cycle changes, increased house soiling, and activity change. There is no cure for the disease.

Ropesalazine is a multi-target drug to prevent both inflammation and free radicals that contribute to nerve cell death, amyloid plaque production, and neurofibrillary tangle formation which are pathological hallmarks of AD.

Ropesalazine was found to attenuate nerve cell death and amyloid plaques as well as inflammation and oxidative stress in transgenic AD mice models. Ropesalazine reduced cognitive deficit in APP/PS1 AD mice at early, moderate, and late stages. The safety of Ropesalazine was proven in human as well as rats and dogs.

GNT Pharma scientists noticed that CDS is accompanied by nerve cell death, amyloid plaques, and neurofibrillary tangles similar to AD, and designed a pilot study to investigate if Ropesalazine would alleviate signs of CDS.

The study was conducted on six companion dogs aged 10 or older that revealed severe cognitive dysfunction scored according to canine cognitive dysfunction rating scale and canine dementia scale. Within 8 weeks following daily oral administration of Ropesalazine, all six dogs returned to the normal range of cognitive function and daily activity.

Dr. Jae Bong Moon, veterinarian and head of Irion Animal Hospital in Seoul who led the study, was excited with the result, saying “The companion dogs failed to recognize their owners before the treatment. It was so amazing to see the dogs that wagged their tails for their owners and cuddled up to them within 8 weeks of Ropesalazine treatment. Ropesalazine appeared to cure CDS.”

Encouraged with promising efficacy of Ropesalazine for CDS, GNT Pharma will move toward the next clinical study for approval of Ropesalazine as a drug for the treatment of CDS. The company assigned Professor Byeong-Teck Kang, director of Chungbuk National University Veterinary Medical Center, as a principal investigator. GNT Pharma plans to complete the clinical trial and launch Ropesalazine for the treatment of CDS in companion animals in 2019.

“We are impressed with such a huge beneficial effect of Ropesalazine for CDS even within 8 weeks of treatment,” GNT Pharma CEO & President Byoung Joo Gwag said, “we will initiate a pivotal phase II study of Ropesalazine for patients with AD next year, hoping to launch Ropesalazine as the first disease-modifying AD therapy within next five years.”

Contact information

GNT Pharma
Dr. Jin Hwan Lee
jhlee@gntpharma.com
Tel. +82-31-8005-9910 (EXT.217)
Fax. +82-31-8005-9916

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Project Management Institute Launches New Reports on Navigating the New Normal of Disruptive Technologies During Seventh Annual PMO Symposium®12.11.2018 16:43Pressemelding

Project Management Institute (PMI) today unveiled three thought leadership reports focused on navigating the new normal of disruptive technologies. The new reports were released during the organization’s seventh annual PMO Symposium® in Washington D.C., where more than 650 of the world’s top project management office (PMO) executives, organizational leaders and senior decision makers have gathered to discuss how disruptive technologies—such as cloud solutions, internet of things (IoT) and artificial intelligence (AI)—have changed the way organizations do business and transformed entire industries. Throughout 2018, PMI and partners, have been exploring disruptive technologies and how organizations are using them to achieve their goals in these changing times. While no one single factor can drive benefits realization, leading organizations understand that proven project management practices lead to greater success and less waste. Produced in partnership with Accenture, PMI’s report — For

Separate Independent Studies Found that PREVENA™ Therapy Reduced Complications Following Breast Cancer Surgery and Breast Reconstruction12.11.2018 14:00Pressemelding

KCI, an Acelity Company, announced today that recently published data stemming from two studies demonstrate that closed incision negative pressure therapy (ciNPT) with the PREVENA™ Incision Management System reduced postsurgical wound complication potential in patients recovering from oncological breast surgery and breast reconstruction, respectively. One study titled, “The Impact of Closed Incision Negative Pressure Therapy on Postoperative Breast Reconstruction Outcomes,” showed that patients who received ciNPT with the PREVENA™ System had significantly lower rates of overall complications and returns to the operating room compared to those in the standard of care (SOC) for incision management after breast reconstruction post-mastectomy group. In addition, patients in the PREVENA™ Therapy group overall had a shorter mean time to complete removal of all drains than the SOC group, averaging 9.9 days versus 13.1, respectively.1 In a separate study titled, “Closed Incision Negative Press

Itron Invites Innovators to Participate in Smart City Challenge12.11.2018 13:45Pressemelding

Itron, Inc. (NASDAQ: ITRI) is calling for hardware and software vendors to submit their products and solutions to the inaugural Itron Smart City Challenge. IoT solution providers will compete for the chance to work with leading smart cities, including Glasgow and the City of London, to deploy breakthrough solutions. Applications are due by Jan. 4, 2019. Participants are invited to develop solutions to address challenges defined by the participating cities. Glasgow: Improve travel choices and experience during events in the city while promoting the overall city center offer The City of Glasgow is one of the world’s top sporting cities and a major destination for conferences and concerts. Many thousands of people come to the city on a regular basis to experience its year-round calendar of events. However, this brings significant challenges in getting people safely and conveniently around the city to their location. It also impacts residents and particularly, the public transport system.

US-Based Lineage Logistics Acquires UK Cold Storage, Frozen Food and Logistics Service Provider Yearsley Group12.11.2018 12:00Pressemelding

Lineage Logistics Holdings, LLC (“Lineage” or the “Company”), the world’s most innovative and trusted provider of temperature-controlled supply chain solutions, today announced it has acquired Yearsley Group Limited (“Yearsley”), a leading temperature-controlled logistics service provider and frozen food distributor in the UK. Financial terms of the transaction were not disclosed. “Yearsley has demonstrated a strong commitment to developing longstanding, bespoke customer relationships that is consistent with how we do business at Lineage. Bringing Yearsley into the Lineage family enables us to better serve customers in the UK market and further reinforces our international logistics capabilities,” said Greg Lehmkuhl, President and Chief Executive Officer of Lineage Logistics. “Our acquisition by Lineage is a tremendous opportunity for Yearsley customers and employees alike,” said Jonathan Baker, Chief Executive of Yearsley Group. “Lineage’s commitment to innovation and service is unmat

B2BX Cryptocurrency Exchange Secures Full Regulatory Approval in Estonia12.11.2018 09:29Pressemelding

B2BX Exchange, a leading professional digital asset trading platform, announced today that it has received approval for a regulatory licence from the Estonian Financial Intelligence Unit (FIU). The licence means that B2BX will be able to operate as a completely regulated exchange for trading cryptocurrencies and makes it one of the first exchanges in Europe to secure this form of recognition. B2BX Exchange, part of the B2Broker group of companies, applied for its licence in Estonia due to the country’s reputation for being highly innovative and technology-friendly. Furthermore, the EU-member country continues to take a leading stance in the advancement of blockchain technologies and cryptocurrency regulation. The licence, which comes into effect shortly, will open the door for B2BX Exchange to provide an extended level of services which currently includes a crypto-to-crypto service and soon to be crypto-to-fiat, as well as providing peace of mind for B2BX Exchange users by way of incre

GSMA Elects New Board Members and Announces Orange Chairman and CEO Stéphane Richard as Chair12.11.2018 09:00Pressemelding

The GSMA today announced that it has elected new members of the GSMA Board for the two-year period from January 2019 through December 2020. The GSMA Board has also elected Stéphane Richard, Chairman and Chief Executive Officer of Orange Group as Chair, and Chua Sock Koong, Group Chief Executive Officer of Singtel Group as Deputy Chair. As GSMA Chair, Richard will oversee the strategic direction of the organisation, which represents more than 750 of the world’s mobile operators, as well as over 350 companies in the broader mobile ecosystem. “I am honoured to be elected to serve as Chair of the GSMA and look forward to working closely with the rest of the Board, the GSMA leadership team and our entire membership to address the critical issues facing our industry and our customers,” said Stéphane Richard, Chairman and Chief Executive Officer of Orange. “Mobile operators and our wider industry have a key role to play in promoting a safer and more inclusive digital world, while building the